JAK2 and Alzheimer disease: Furthermore, plasma β-amyloid (40/42) levels are increased in Alzheimer’s disease patients with hyperglycemia and they exacerbate hepatic insulin resistance by activating Janus kinase-2 signaling in the liver [50].